Pharmacogenomics of autism spectrum disorder (Q39154436)

9 September 2017

title

Pharmacogenomics of autism spectrum disorder (English)

1 reference

9 September 2017

main subject

autism spectrum disorder

0 references

0 references

1 reference

Edwin H Cook

1 reference

9 September 2017

Jacob T Brown

1 reference

9 September 2017

Seenae Eum

series ordinal

1 reference

9 September 2017

Jeffrey R Bishop

series ordinal

1 reference

9 September 2017

publication date

22 February 2017

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

page(s)

403-414

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

9 September 2017

1 reference

Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years--Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Identification and Evaluation of Children With Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Complex genomic variants contribute toward the genetic architecture of autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Autism: highly heritable but not inherited

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Characteristics and concordance of autism spectrum disorders among 277 twin pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Synaptic, transcriptional and chromatin genes disrupted in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Common genetic variants on 5p14.1 associate with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

A genome-wide scan for common alleles affecting risk for autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Common genetic variants, acting additively, are a major source of risk for autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Rare inherited variation in autism: beginning to see the forest and a few trees

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Genetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Risperidone for autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

The effect of antidepressants and antipsychotics on weight gain in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Healthcare transition challenges faced by young adults with autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Gene expression in blood is associated with risperidone response in children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Genetics of Common Antipsychotic-Induced Adverse Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Prolactin levels and adverse events in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Prolactin and dopamine: what is the connection? A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS-2016-0167

21 January 2018

Identifiers

DOI

10.2217/PGS-2016-0167

1 reference

9 September 2017

1 reference